 Lowering the rate of recurrent CDI via use of ridinilazole could save the U.S. healthcare system $30,000 per patient due to a decreased number of hospitalizations., there is currently an ongoing Phase II clinical trial underway in the US comparing ridinilazole with fidaxomicin in the treatment of CDI.The partner with Summit Therapeutics must conduct 2 randomized, double-blind trials comparing ridinilazole to vancomycin or fidaxomicin.